Polymyxin B hemoperfusion as a feasible therapy after source control in abdominal septic shock

Table 2 Characteristics of patients, laboratory findings, and treatment of sepsis in propensity-matched groups

	PMX-HP (n = 20)	Control (n = 20)	P value
Primary infection site, n (%)			0.166
Upper GI tract	0 (0.0)	3 (15.0)
Small bowel	4 (20.0)	7 (35.0)
Lower GI tract	14 (70.0)	10 (50.0)
Hepatobiliary system	1 (5.0)	0 (0.0)
Soft tissue infection	1 (5.0)	0 (0.0)
Microorganisms, n (%)
Gram-negative species	11 (55.0)	10 (50.0)	0.752
Gram-positive species	6 (30.0)	7 (35.0)	0.736
Fungus	4 (20.0)	3 (15.0)	0.677
No growth	5 (25.0)	7 (35.0)	0.490
Number of microorganisms, n (%)			0.747
Single microorganism	9 (45.0)	7 (35.0)
Multiple microorganisms	6 (30.0)	6 (30.0)
Laboratory test on admission
WBC, 109/L	87.6 ± 64.9	94.0 ± 49.1	0.731
Platelet counts, 109/L	130.0 ± 102.0	163.7 ± 133.5	0.375
Hb, g/L	9.6 ± 2.0	10.5 ± 2.2	0.178
PT, %	45.7 ± 24.4	55.0 ± 16.5	0.168
Lactate, mmol/L	7.8 ± 6.9	7.2 ± 3.1	0.738
Methods of infection control, n (%)			1.000
Surgical intervention	19 (95.0)	19 (95.0)
Radiologic intervention	1 (5.0)	1 (5.0)
Other therapeutic management, n (%)
pRBC transfusion, n (%)	11 (55.0)	19 (95.0)	0.006
Mechanical ventilator	14 (70.0)	16 (80.0)	0.537
Re-intubation	3 (15.0)	2 (10.0)	0.633
RRT	9 (45.0)	8 (40.0)	0.749

GI: Gastrointestinal system; Hb: Hemoglobin; pRBC: Packed red blood cells; PT: Prothrombin tine; RRT: Renal replacement therapy; WBC: White blood cell count; PMX-HP: Polymyxin B hemoperfusion.